GSK

Business Context and Reporting Period

This Form 6-K filing by GSK plc covers the month of October 2025, with a specific reporting date of October 15, 2025. The document serves as a transaction notification detailing share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The transactions occurred on October 10, 2025, primarily on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS).

Key Financial Metrics and Transaction Details

The filing does not contain corporate financial statements such as revenue, profit, cash flow, or debt levels. Instead, it reports specific share transaction metrics:

• Instrument: Ordinary Shares (31½ pence each, ISIN: GB00BN7SWP63) and American Depositary Shares (ADSs, ISIN: US37733W2044).
• Transaction Price (Ordinary Shares): Predominantly £16.4000 per share. Two transactions by David Redfern and Victoria Whyte occurred at £16.3499.
• Transaction Price (ADSs): $43.4400 per ADS (Shobie Ramakrishnan).
• Total Volume: Multiple transactions totaling thousands of shares across 12 executives.
• Transaction Nature: Increases in notional interest or acquisitions resulting from the re-investment of dividends paid on October 9, 2025.

Material Changes and Transaction Drivers

The reported changes in shareholdings are not the result of open market purchases for personal investment but are automatic re-investments of dividends. The transactions fall into three categories:

1. Deferred Annual Bonus Plan: The majority of executives (including CEO Emma Walmsley, CFO Julie Brown, and others) acquired shares via dividend re-investment on shares held in this plan.
2. Performance Share Plan: CEO Emma Walmsley acquired 8,786.741 shares subject to a 2-year holding period via dividend re-investment.
3. Individual Savings Accounts (ISA): David Redfern and Victoria Whyte acquired small volumes (20 and 17 shares respectively) via dividend re-investment within ISAs.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, financial guidance, outlook, or risk factors. It is a statutory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. No unusual items or contingencies are disclosed in this specific document.

Investor Verification Checklist

• Verify the dividend payment date of October 9, 2025, to confirm the timing of the re-investment.
• Confirm the share price of £16.4000 on the London Stock Exchange for October 10, 2025.
• Review the specific terms of the Deferred Annual Bonus Plan and Performance Share Plan to understand vesting schedules and holding periods.
• Note that these transactions represent passive accumulation of equity via dividends rather than active market sentiment signals.